Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2024
0mins
Should l Buy ?
Source: Newsfilter
Completion of Clinical Trial Enrollment: Acasti Pharma has completed patient enrollment for its Phase 3 STRIVE-ON safety trial of GTX-104, an injectable formulation of nimodipine aimed at treating aneurysmal subarachnoid hemorrhage (aSAH), with results expected in early 2025.
Potential Impact and Market: GTX-104 could improve treatment for aSAH patients by providing intravenous delivery, potentially eliminating complications associated with oral administration, and the U.S. market for this drug is estimated to be around $300 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
